ReviewBMC nephrology2025
Targeting panoptosis: a narrative review of its therapeutic potential in kidney disease.
Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Autophagy determines the fate of immune cells by regulating metabolic remodeling and PANoptosis (Review).International journal of molecular medicine · 2026Review
- Targeting integrated cell death networks in sepsis‑associated acute kidney injury: Shared regulatory nodes and diet‑related small molecule modulation (Review).International journal of molecular medicine · 2026Review
- Sodium Danshensu Attenuates Renal Ischemia-Reperfusion Injury by Suppressing STAT3-Driven Cytokine Signaling and Apoptosis.Chinese journal of integrative medicine · 2026Article
- Studies on Zinc Metabolism Related to Ischemia-reperfusion Injury: A Bibliometric and Visualized Analysis.Biological trace element research · 2026Review
- Targeting pyroptosis in renal fibrosis: From molecular mechanisms to therapeutic horizons (Review).International journal of molecular medicine · 2026Review
- Dynamin-Related Protein 1 (Drp1) in Inflammatory Bowel Disease: Molecular Pathways Connecting Mitochondrial Dynamics with Intestinal Inflammation and Homeostasis.International journal of molecular sciences · 2026Review
- Apoptosis as an evolutionary battleground: pathogen pressure and the shaping of programmed cell death pathways.Frontiers in cell and developmental biology · 2026Review
- Cross-talk among novel programmed cell death pathways: a decisive network in renal ischemia-reperfusion injury.Frontiers in immunology · 2026Review
- PANoptosis nexus in ischemia-reperfusion injury: from integrated cell death mechanisms to novel therapeutic opportunities.Frontiers in immunology · 2026Review
- Recent advances in PANoptosis research in kidney disease: mechanistic networks, pathological roles, and potential intervention strategies.Frontiers in immunology · 2026Review
- Ferroptosis regulation by SGLT2 inhibitors: mechanisms and clinical benefits in diabetic kidney disease.Frontiers in pharmacology · 2026Review
- The Inflammatory Cell Death in Diabetic Kidney Disease: Integrating Multifactorial Mechanisms into Novel Therapeutics.International journal of molecular sciences · 2025Review
- PANoptosis: a potential target of cardiomyopathy.Frontiers in immunology · 2025Review
- Balanophora polysaccharide improves renal injury and fibrosis in db/db diabetic nephropathy mice via NLRP3 inflammasome mediated inflammation.Frontiers in pharmacology · 2025Article
- Hyperoside ameliorates lupus nephritis by suppressing AKT1-mediated PANoptosis in podocytes: integrating network pharmacology and experimental validation.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Renal diseases are major global public health challenges due to their complex mechanisms and growing burden. PANoptosis, a unified programmed cell death pathway driven by the PANoptosome complex, involves the combined activation of pyroptotic, apoptotic, and necroptotic signaling, significantly contributing to renal tissue damage. This review systematically explores PANoptosis's composition, regulatory mechanisms, and its role in kidney pathologies such as AKI, CKD, DKD, and renal tumors. It also examines the interplay between PANoptosis and key cellular processes like mitochondrial dysfunction, ER stress, non - coding RNAs, ferroptosis, and autophagy. Preclinical studies suggest that targeting PANoptosis - related molecules (e.g., Z-DNA Binding Protein 1(ZBP1), caspase - 8, NOD-like receptor thermal protein domain associated protein 3(NLRP3)) shows therapeutic potential for kidney diseases. However, clinical application is currently limited due to insufficient human data. Future research should focus on validating PANoptosis biomarkers in renal diseases, developing cell - death - context - specific inhibitors and agonists, and clarifying its advantages over single - mode cell death modulation. This review highlights PANoptosis as a promising therapeutic strategy while addressing unresolved issues in nephrology research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.